Testing a single pill for hard-to-control high blood pressure in Brazil
Compares one combined pill with usual care in adults with resistant hypertension.
Plain-language title generated from the registry record
Registry title: Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)
Key facts
- Where
- São Paulo, BrazilSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 whose high blood pressure stays above target despite taking 3 to 5 classes of blood pressure medicine, and who have trouble taking their medicines as prescribed.
- Age
- 18 to 75 years
- Sex
- Men and women can join.
- Disease stage
- Apparent resistant high blood pressure: office blood pressure 140/90 mmHg or higher, and 24-hour blood pressure monitoring (ABPM) done within the last month showing 130/80 mmHg or higher.
- Earlier treatment
- Must already take 3 to 5 classes of blood pressure medicine, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB).
- Biomarker or test result
- Poor adherence to treatment: a score of 1 point or more on the Morisky Medication Adherence Scale (MMAS-4).
Main reasons for not taking part
- Secondary hypertension (for example hyperaldosteronism, pheochromocytoma or renovascular hypertension)
- Past intolerance or side effects to ACE inhibitors, thiazide or thiazide-like diuretics, or calcium channel blockers
- Atrial fibrillation or atrial flutter, or use of oral anticoagulants
- Severe kidney problems (creatinine clearance or eGFR below 30)
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07259733, who can take part
Where in Brazil
- Instituto Dante Pazzanese de CardiologiaSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Instituto Dante Pazzanese de Cardiologia
- Trial code
- NCT07259733
- Record updated
- 2 December 2025
- Original description
This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.Read full original descriptionShow less
Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)
This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.
Inclusion: Treatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB); Recent 24-hour ambulatory blood pressure monitoring (ABPM) (<1 month) showing values above target (24-hour BP ≥130/80 mmHg); Office blood pressure ≥140/90 mmHg; Poor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4); -.
Exclusion: Significant valvular heart disease; Severe psychiatric disorders; History of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache); Reduced left ventricular ejection fraction (LVEF < 55%); Severe renal impairment (creatinine clearance < 30 mL/min or eGFR < 30 mL/min/1.73 m²); Active malignancy with life expectancy < 2 years; Indispensable use of beta-blockers or mineralocorticoid receptor antagonists; Office blood pressure ≥ 220 × 120 mmHg; Atrial fibrillation or atrial flutter; Use of oral anticoagulants; Body mass index (BMI) ≥ 40 kg/m²; Pregnant or breastfeeding women; -.